Objectives: One of the home-made herbal remedy being traditionally used against gout is evaluated to identify any new and characteristic marker compound which may be used as characteristic analytical marker to standardize this polyherbal remedy. Materials and method: A distinct and remarkable peak in the HPLC chromatogram of remedy was identified which was further isolated by fraction collector. This fraction was then evaporated and characterized for structure elucidation using set of various techniques such as RP-HPLC,UV, FTIR, TLC, EIMS and NMR. Results: The compound characterized was non polar compound, ester of betulin and palmitoleic acid. Although the remedy has been standardized using set of four markers as discussed in literature but this newly developed marker compound can be used to further standardize this remedy and other herbal preparations comprising of this marker compound.Conclusion: Hence the isolated compound can be used as novel analytical marker in the standardization of this herbal remedy and the other herbal preparations containing such marker compound

Influenza is well-known to have a considerable influence on healthcare system, therefore, vaccination plays a significant role in dealing with severe consequences. Close attention is paid to the development of tetravalent adjuvanted vaccines, containing antigens of two influenza A subtypes (H1N1, H3N2) and two influenza B subtypes (Victoria, Yamagata) to increase the effectiveness of influenza prevention. In this work we present the results of pre-clinical study of innovative subunit tetravalent candidate influenza vaccine, with addition of betulin as adjuvant, TetraFluBet. The study was conducted using female BALB/c mice, male and female mongrel rats and guinea pigs. TetraFluBet and commercially available vaccines were injected intraperitoneally twice in a 14-day interval after intranasal infection with 5LD50 and 10LD50. Chronic toxicity was assessed by immunohistochemistry of extracted organs and by hematological and biochemical blood parameters. Protectivity and immunogenicity were evaluated using hemagglutination inhibition and microneutralization with MDCK assays. Chronic toxicity study did not reveal any side effects of candidate TetraFluBet vaccine on both rats and guinea pigs. One vaccination dose of TetraFluBet provided 100% protectivity against all 4 influenza subtypes and significantly increased neutralizing antibody activity in response to immunization of influenza subtypes. Pre-clinical candidate vaccine TetraFluBet confirmed its safety along with specific activity, showed high immunogenicity and can be recommended for further clinical studies.